Attune Xenith Flow Cytometer

The National Institutes of Health (NIH) intends to negotiate and award a Firm-Fixed-Price purchase order for the acquisition of one Thermo Fisher Scientific Attune Xenith Spectral Flow Cytometer. The required system must provide spectral flow cytometry capability, conventional compensation-based flow cytometry capability, and other specific features. The Government believes that Thermo Fisher Scientific / Life Technologies Corporation is the only responsible source capable of providing a system that meets the Government’s minimum needs. • The system must have spectral flow cytometry capability with full-spectrum fluorescence detection and spectral unmixing • The system must have conventional compensation-based flow cytometry capability to support continuity with existing assays and workflows • The system must have a minimum six-laser optical configuration, including ultraviolet (UV), violet, blue, yellow-green, red, and near-infrared (NIR) • The system must have minimum 51 fluorescent detectors and 6 scatter detectors • The system must have acoustic-assisted hydrodynamic focusing technology • The system must have high-throughput sample acquisition capability • The system must be compatible with complex biological samples, including tumor, tissue, blood, and cellular therapy samples • The system must be compatible with an automated sample loading system capable of processing 96-well and 384-well plate formats • The system must include the CytKick Max automated sample loader • The system must have integrated instrument control and analysis software for acquisition, spectral analysis, quality control, and data export • The system must have touchscreen operation and automated maintenance functions • The system must have remote diagnostics and manufacturer-supported service support • The system must have vendor-provided installation, startup, training, and warranty coverage